Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

Modified aminoglycosides designed for nonsense suppression therapy in genetic diseases

March 18, 2011

Seattle Genetics and Millennium extend antibody-drug conjugate agreement

March 16, 2011

Omeros identifies selective interactors of two orphan receptors

March 3, 2011

MorphoSys receives milestone payment from Novartis in connection with HuCAL technology

Feb. 22, 2011

Modified mRNA molecules could be alternatives to DNA-based therapies

Feb. 21, 2011

Pfenex and Boehringer Ingelheim form strategic alliance for novel technology

Feb. 17, 2011

Overall success rate of clinical drug development is 9%

Feb. 17, 2011

New model developed to evaluate pharmacodynamics of antimicrobial agents and design dosing regimens

Feb. 15, 2011

Aptamer-targeted nanoparticle-encapsulated cisplatin prodrug shows promise in vivo

Feb. 11, 2011

Elan and Boehringer Ingelheim to codevelop antibody-based therapeutics

Feb. 9, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...